The Biomarker Laboratory offers diagnostic service of biomarkers of Alzheimer’s disease form blood (pTau181, pTau217) and CSF (beta-amyloid 42, Tau, pTau181) and of neurofilament light chain (Nfl) from blood samples. Results from biomarker analysis facilitate correct and early identification of Alzheimer’s disease.

Plasma pTau181 testing supports clinical decision-making, particularly in the early evaluation of memory symptoms and in guiding further diagnostic investigations. Measurement of the phosphorylated tau protein form pTau181 in plasma can be used in individuals over 55 years of age who show signs of cognitive impairment. Plasma pTau181 has an excellent negative predictive value: a negative result strongly suggests that Alzheimer’s disease is unlikely to be the underlying cause of the symptoms. The analysis method is Roche Elecsys immunoassay.

Plasma pTau217 is a novel non-invasive biomarker for Alzheimer’s disease. The blood test is not recommended for individuals under 50 years of age or for asymptomatic individuals. An elevated level of pTau217 is an indication of Alzheimer’s disease-associated changes in the brain, but these changes do not always lead to illness. The blood test can, together with memory studies and other clinical findings, provide support for an Alzheimer’s diagnosis, and it will be up to the attending physician to decide whether the test is needed. The analysis utilizes Fujirebio Lumipulse technology.

Biomarker Laboratory has ISO 15189 accreditation for CSF beta-amyloid 42, Tau and pTau181 analyses (Li-BAm42, Li-Tau, Li-FosTau), which are run using Roche Elecsys immunoassays.

Neurofilament light chain (NfLc) is a biomarker for nervous system injury. It is measured from blood sample (preferably EDTA-plasma) using Roche Elecsys immunoassay.

The laboratory also actively conducts scientific research, including the development of Alzheimer’s analytics and studies related to biomarkers for other neurological diseases.

See our pages in Finnish here.

Updated 2.4.2026